We suggest that CLU and PPARGC1A are indispensable for controlling mitochondrial content during chemotherapeutic stress and that modulating their activity could strongly influence therapeutic responses in oral cancer. This evidence concerns the gene CLU and lip and oral cavity carcinoma.